Breath-Based Cancer Diagnostics
Cancer Detection. From a Single Breath.
Exhale Science is developing a non-invasive diagnostic platform that detects cancer and pre-cancer by analyzing volatile organic compounds (VOCs) in exhaled breath — enabling earlier detection, better outcomes.
Our Mission
The earliest cancer signal may already be in your breath.
Volatile organic compounds produced by cancerous and pre-cancerous cells are exhaled with every breath. Exhale Science has developed the technology to detect, identify, and interpret these molecular signatures — making cancer screening as simple as breathing into a device.
The Technology
Molecular diagnostics through exhaled breath analysis.
Our platform captures and analyzes the volatile organic compound (VOC) profile of a patient's exhaled breath. Using advanced mass spectrometry and AI-driven pattern recognition, we identify the molecular fingerprints of cancer and pre-cancer with clinical-grade accuracy.
Breath Sample Collection
Patients exhale into our proprietary collection device. The process is non-invasive, painless, and takes under two minutes.
VOC Analysis
Exhaled breath is analyzed for volatile organic compounds — small molecules produced by metabolic activity in cancerous and pre-cancerous cells.
AI-Driven Pattern Recognition
Our machine learning models identify VOC signatures associated with specific cancer types, trained on clinically validated datasets.
Clinical-Grade Diagnostic Report
Results are delivered as a structured diagnostic report, enabling clinicians to act on early-stage findings with confidence.
How It Works
From breath sample to diagnostic insight.
Breath Collection
The patient exhales into our non-invasive collection device. No needles, no contrast agents, no radiation — just a breath sample.
VOC Extraction & Analysis
The sample is processed to isolate and identify volatile organic compounds present in the exhaled breath using high-sensitivity analytical instrumentation.
AI Biomarker Interpretation
Our AI platform cross-references the VOC profile against validated cancer biomarker signatures, identifying patterns associated with malignancy.
Diagnostic Report
A clinical-grade report is generated, flagging findings for physician review and enabling early intervention when it matters most.
The Research
Grounded in the science of breath-based diagnostics.
The link between exhaled VOCs and cancer has been established in peer-reviewed literature for decades. Exhale Science builds on this foundation with proprietary analytical methods, clinical partnerships, and AI models trained on real patient data to bring breath-based cancer diagnostics to clinical practice.
The Team
Scientists, clinicians, and technologists united by a mission.
Arie Laor
Co-Founder & Chief Technology Officer
Serial entrepreneur in diagnostics and breath-analysis ventures; international clinical-study experience. Claims are company-reported.
Trevor Thera
Co-Founder & CEO
Public, private and academic partnership development; leading Alberta investigator and funding engagement.
Moshe Schaffer
Chief Medical Officer
Oncologist with 25+ years of clinical and research experience; former cancer-research leadership and patent activity are company-reported.
Yaakov Brezel
Founder & Chief Business Officer
North American medtech business development and regulatory-pathway experience; strategic transaction experience is company-reported.
Earlier detection saves lives. Let's make it accessible.
We're partnering with clinicians, research institutions, and health systems to bring breath-based cancer diagnostics to patients. Get in touch to learn more.
We welcome inquiries from clinicians, researchers, and potential partners.